ENFERMEDAD CARDIOVASCULAR EN LA MUJER: FISIOPATOLOGÍA, PRESENTACIÓN CLÍNICA, FACTORES DE RIESGO, TERAPIA HORMONAL Y PRUEBAS DIAGNÓSTICAS

Ford, 2007, Explaining the decrease in US deaths from coronary disease 1980-2000, N Eng J Med., 356, 2388, 10.1056/NEJMsa053935 Corbalan, 2002, Reducción de la Mortalidad por infarto del miocardio en hospitales chilenos, Rev. Med. de chile, 130, 368, 10.4067/S0034-98872002000400003 Kunstmann, 2007, Salud Cardiovascular en la mujer, Rev. Mèc)dica Clínica Las Condes, 18, 173 Wenger, 2003, Coronary heart disease: The female heart is vulnerable, Prog Cardiovasc Dis., 46, 199, 10.1016/j.pcad.2003.08.003 Pepine, 2004, Women's ischemic syndrome evaluation. Current status and future research directions: Report of the National Heart, Lung and Blood Institute, Circulation, 109, e44, 10.1161/01.CIR.0000116206.77324.5B Patel, 2004, Symptomsinacutecoronarysyndromes: Does sex make a difference?, American Heart Journal, 148, 27, 10.1016/j.ahj.2004.03.005 Kunstmann, 2004, Riesgo de presentar un evento cardiovascular a 10 años en personas sanas: Proyecto RICAR. Estudio de Prevención de Riesgo Cardiovascular, Sociedad Chilena de Cardiología y Cirugía Cardiovascular. Revista Chilena de Cardiología, 23, 13 Lira, 2004, Cardiovascular Risk Factors in Primary Prevention: Knowledge, Attitude Awareness and stage of behaviour change in 12.500 Chilean People, Circulation, 109, 20 Sekikawa, 2013, Do differences in risk factors explain the lower rates of coronary heart disease in Japanese versus U.S. women?, Journal of Women's Health, 22, 966, 10.1089/jwh.2012.4087 Kunstmann, 2009, Enfermedad Cardiovascular en la Mujer y su relación con la menopausia, Rev. Medica Clínica Las Condes, 20, 39 Kunstmann, 2006, High blood Pressure and Diabetes Play an Important Role in the Development and Prognosis of Myocardial Infarction in Women, Atherosclerosis, 7, 65, 10.1016/S1567-5688(06)80224-2 Wenger, 2001, CHD in women: clinical characteristics, gender differences and outcome improvement, Menopause Management, 10, 26 Hecht, 2001, Electron beam tomography and National Cholesterol Education Program guidelines in asymptomatic women, J Am Coll Cardiol., 37, 1506, 10.1016/S0735-1097(01)01211-6 Nasir, 2005, Detection of high-risk young adults and women by coronary calcium and National Cholesterol Education Program Panel III guidelines, J Am Coll Cardiol, 46, 1931, 10.1016/j.jacc.2005.07.052 Cook, 2006, The effect of including C-reactive protein in cardiovascular risk prediction model for women, Ann Intern Med, 145, 21, 10.7326/0003-4819-145-1-200607040-00128 Wong, 2001, Distribution of C reactive and its relation to risk factors and coronary heart disease risk estimation in the National Health and Nutrition Examination Survey (NHANES) III, Prev Cardiol, 4, 109, 10.1111/j.1520-037X.2001.00570.x Ridke, 2003, C-reactive protein, metabolic syndrome, and risk of incident cardiovascular events: an 8 year follow up of 14719 initially healthy America women, Circulation, 107, 391, 10.1161/01.CIR.0000055014.62083.05 Spencer, 2008, For the Million Women Study Collaborators. Diabetes and modifiable risk factors for cardiovascular disease: The prospective Million Women Study, Eur J Epidemiol, 23, 793, 10.1007/s10654-008-9298-3 Kanaya, 2002, Explaning the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analisis, Arch Intern Med, 162, 1737, 10.1001/archinte.162.15.1737 Kunstmann, 2009, Dislipidemia en la mujer: Diagnostico, clasificación y manejo, Rev. Medica Clínica Las Condes, 20, 47 Ogden, 2006, Prevalence of overweight and obesity in the United States, 1999-2004, JAMA, 295, 549, 10.1001/jama.295.13.1549 McTigue, 2006, Mortality and cardiac and vascular outcomes in extremely obese women, JAMA, 296, 79, 10.1001/jama.296.1.79 Mendelshon, 1999, The protective effects of estrogens on the cardiovascular system, N Engl J Med, 340, 1801, 10.1056/NEJM199906103402306 Arteaga E. Riesgo cardiovascular en el Climaterio. En: Consenso en Climaterio 2001. Una recomendación fundamentada. Eds. E Arteaga, P Contreras y O González. Ediciones Sociedad Chilena de Climaterio. Editorial Bywaters, Santiago 2001 pp 61-73. Hulley, 1998, for the Heart Estrogen-progestin Replacement Study (HERS) Research Group Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women, JAMA, 280, 605, 10.1001/jama.280.7.605 Grady, 2002, for HERS Research Group Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II), JAMA, 288, 49, 10.1001/jama.288.1.49 Kanaya, 2003, Glycemic effects of postmenopausal hormone therapy: The Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial, Ann Intern Med., 138, 1, 10.7326/0003-4819-138-1-200301070-00005 Herrington, 2002, Statin therapy cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS), Circulation, 105, 2962, 10.1161/01.CIR.0000019406.74017.B2 Writing Group for the Women's Health Initiative Investigators.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-33. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701-12. Manson, 2007, Estrogen therapy coronary-artery calcification WHI-Coronary Artery Calcium Study (WHI-CACS), New Engl J. Med, 356, 2591, 10.1056/NEJMoa071513 Grodstein, 2006, Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation, J Women's Health., 15, 35, 10.1089/jwh.2006.15.35 Salpeter, 2006, Brief Report: Coronary heart disease events associated with hormone therapy in younger and older woman. A meta-analysis, J Gen Intern Med., 21, 363, 10.1111/j.1525-1497.2006.00389.x Straczek, 2005, for the Estrogen and Thromboembolism Risk (ESTHER) Study Group, Circulation., 112, 3495, 10.1161/CIRCULATIONAHA.105.565556 Harman, 2014, Arterial Imaging outcomes and cardiovascular risk factors in recently menopausal women KEEPS, Ann. Intern Med, 1 US Food and Drug Administration. FDA Updates: hormone therapy information for postmenopausal women (2004). www.fda.gov/bbs/topic/NEWS/2004/NEW01022.html. The Board of Trustees of the North American Menopause Society, 2010, Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society, Menopause, 17, 242, 10.1097/gme.0b013e3181d0f6b9 Ng, 2013, Diagnosing and characterizing coronary artery disease in women: Developments in noninvasive and invasive imaging techniques, J. Cardiovascular Trans Res., 6, 740, 10.1007/s12265-013-9500-1